Business Wire

Sandvine Appoints Chief Ethics & Compliance Officer and Board Advisor as Part of Strengthened Commitment to Internet Freedom and Digital Rights

15.1.2025 18:41:00 CET | Business Wire | Press release

Share

Carol Tate will serve as CCO following her tenure as Chief Compliance Officer at IntelFormer President & CEO of Human Rights First, Michael Breen, appointed as Advisor to the Board of Directors

Today, Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, announced the appointments of Carol Tate as Chief Ethics & Compliance Officer, effective February 3, and Michael Breen as Advisor to the Board of Directors, effective January 1. Working closely with teams across the Company and in collaboration with its Board of Directors, Tate will spearhead compliance and due diligence initiatives to help facilitate Sandvine’s transition into a technology solution leader for democracies. Working directly with the Company’s Board of Directors, Breen is advising on human rights matters, including its engagement with non-governmental organizations to inform the Company’s human rights due diligence.

With decades of legal, risk, and compliance experience in the public and private sectors, Tate brings extensive experience embedding ethics and compliance into technological deployment and innovation on a global scale. She most recently served as Vice President and Chief Compliance Officer at Intel Corporation (NASDAQ: INTC) (“Intel”), where she led the organization’s global ethics and compliance function, which included driving initiatives to promote the company’s values and ethical culture, encourage open reporting, and reinforce Intel’s commitment to product responsibility in connection with Intel’s technology.

Prior to Intel, Tate held senior leadership roles within the ethics and compliance functions at McCarthy Holdings, Inc., Flextronics International Ltd., and Motorola. She also served as a senior attorney with the U.S. Securities and Exchange Commission’s Enforcement Division.

“As we operate in an increasingly complex digital environment, Sandvine’s focus on driving technological innovation while promoting internet freedom and digital rights could not be more critical,” said Tate. “I am excited to join a team and organization focused on providing high-quality products and premier customer service while facing these challenges head-on through close and productive partnerships with all stakeholders.”

Breen, an executive leader, strategist, policy expert and former military officer, has diverse experience leading complex organizations at the intersection of technology, global security, human rights, politics, and markets. He previously served as President & CEO of Human Rights First, a US-based organization confronting global human rights abuse, authoritarianism, and extremism through technology innovation and deployment, crisis response, policy development and advocacy, research, and legal services. Prior to leading Human Rights First, Breen acted as President & CEO of the Center for National Policy and the Truman National Security Project, served in the Obama administration’s Office of White House Counsel, and co-founded the International Refugee Assistance Project. He began his career as a decorated US Army officer, leading soldiers in combat in Iraq and Afghanistan.

“At a critical inflection point, Sandvine worked diligently to rechart its course, commit to being a positive and material contributor to the protection of human rights around the world, and double down on its mission to help people work, learn, entertain, and communicate. That resilience speaks to the Company’s potential to build itself into a values-driven technology solutions market leader,” said Breen. “I look forward to working closely with the Sandvine Board of Directors and the Company’s executive leadership team to help Sandvine navigate the challenges of today’s digital landscape.”

“Sandvine’s appointments of Carol and Michael are a direct reflection of the Company’s strengthened commitment to internet freedom and both digital and human rights, and we are honored to welcome them aboard,” added Carney Hawks, Chairman of the Board of Sandvine. “Carol’s extensive and successful track record collaborating with government and regulatory stakeholders, customers, trade groups, NGOs, and colleagues to deliver technological excellence governed by the highest ethical standards, combined with Michael’s exceptional background leading organizations dedicated to mitigating the world’s most complex issues across technology, human rights, global security and political dimensions, will be immensely valuable to Sandvine in this new chapter.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115186859/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye